Corrigendum to “N6-methyladenosine modified LINC00901 promotes pancreatic cancer progression through IGF2BP2/MYC axis” [Genes & Diseases 10 (2023) 554–567]
Wan-Xin Peng,
Fei Liu,
Jia-Hong Jiang,
Hang Yuan,
Ziqiang Zhang,
Liu Yang,
Yin-Yuan Mo
Affiliations
Wan-Xin Peng
Department of Surgical Oncology, The Children's Hospital, Zhejiang University School of Medicine, National Research Center for Child Health, Hangzhou, Zhejiang 310052, China; Cancer Center and Research Institute, University of Mississippi Medical Center, Jackson, MS 39216, USA; Corresponding author. Department of Surgical Oncology, The Children's Hospital, Zhejiang University School of Medicine, National Research Center for Child Health, Hangzhou, Zhejiang 310052, China.
Fei Liu
Department of Nephrology, The Children's Hospital, Zhejiang University School of Medicine, National Research Center for Child Health, Hangzhou, Zhejiang 310052, China
Jia-Hong Jiang
Department of Medical Oncology, Zhejiang Provincial People's Hospital, People's Hospital of Hangzhou Medical College, Hangzhou, Zhejiang 310014, China
Hang Yuan
Department of Colorectal Surgery, Zhejiang Provincial People's Hospital, People's Hospital of Hangzhou Medical College, Hangzhou, Zhejiang 310014, China
Ziqiang Zhang
Department of Pulmonary Medicine, Tongji Hospital, Tongji University, Shanghai 200065, China
Liu Yang
Key Laboratory of Tumor Molecular Diagnosis and Individualized Medicine of Zhejiang Province, Zhejiang Provincial People's Hospital, People's Hospital of Hangzhou Medical College, Hangzhou, Zhejiang 310014, China; Corresponding author.
Yin-Yuan Mo
Cancer Center and Research Institute, University of Mississippi Medical Center, Jackson, MS 39216, USA; Department of Pharmacology/Toxicology, University of Mississippi Medical Center, Jackson, MS 39216, USA; Corresponding author. Cancer Center and Research Institute, University of Mississippi Medical Center, Jackson, MS 39216, USA.
